Clinical value of ¹⁸ F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy

¹⁸F-PI-2620 tau-PET can successfully identify patients that progress along expected 4RT clinical spectra. This supports ¹⁸F-PI-2620 tau-PET as a 4RT biomarker, with the potential to facilitate early biomarker-based diagnosis when clinical criteria may still lack sensitivity and specificity. This development can be transformative for clinical decision making, pre-symptomatic identification of PSP and stratifying patients for disease modifying clinical trials.